Last $51.85 USD
Change Today 0.00 / 0.00%
Volume 0.0
TEVJF On Other Exchanges
Symbol
Exchange
New York
OTC US
Mexico
Tel Aviv
Frankfurt
As of 8:10 PM 06/16/14 All times are local (Market data is delayed by at least 15 minutes).

teva pharmaceutical ind ltd (TEVJF) Snapshot

Open
$51.85
Previous Close
$51.85
Day High
$51.85
Day Low
$51.85
52 Week High
04/1/14 - $52.26
52 Week Low
11/18/13 - $38.20
Market Cap
44.1B
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
851.0M
EX-Date
05/20/14
P/E TM
--
Dividend
$477.24
Dividend Yield
2.58%
Current Stock Chart for TEVA PHARMACEUTICAL IND LTD (TEVJF)

teva pharmaceutical ind ltd (TEVJF) Details

Teva Pharmaceutical Industries Limited, together with its subsidiaries, develops, manufactures, sells, and distributes pharmaceutical products worldwide. The company offers generic pharmaceutical products; and basic chemicals, as well as specialized product families. Its products include Copaxone for multiple sclerosis; Azilect for the treatment of Parkinson’s disease; Provigil and Nuvigil to treat excessive sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work disorders; Fentora and Actiq to treat pain in opioid-tolerant adult patients with cancer; and Amrix for muscle spasm in acute, painful, and musculoskeletal conditions. The company also offers Treanda to treat chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma; Tevagrastim that stimulate the production of white blood cells; Lonquex, which reduces the duration of neutropenia and incidence of febrile neutropenia in adult patients; Eporatio that stimulates the production of red blood cells; and Synribo for chronic myeloid leukemia. In addition, it provides ProAir for the treatment of bronchospasm; QVAR for the treatment of asthma; Qnasl Nasal Aerosol for nasal allergy symptoms in adults; Plan B One-Step and Quartette, which prevents pregnancy; Seasonique and LoSeasonique that are extended-cycle oral contraceptives; Zoely, a regimen combination contraceptive oral pill; and ParaGard, a non-hormonal intrauterine contraceptive. Further, the company offers Enjuvia for vasomotor symptoms associated with menopause; hormone therapy treatments for menopause/perimenopause; therapies for infertility and urinary incontinence; and manufactures active pharmaceutical ingredients. It also distributes third party products. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel.

44,945 Employees
Last Reported Date: 02/10/14
Founded in 1901

teva pharmaceutical ind ltd (TEVJF) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

teva pharmaceutical ind ltd (TEVJF) Key Developments

Teva Pharmaceutical Industries Ltd. Files US Food and Drug Administration Citizen Petition on Copaxone

Teva Pharmaceutical Industries Ltd. has filed a citizen petition with the US Food and Drug Administration (FDA) regarding the approvability of generic versions of Copaxone. Teva submitted the petition according to the FDA's procedural guidance and in accordance with the FDA's desire to facilitate public review and comment regarding new scientific data on gene expression. Teva has in fact previously submitted much of this information in its Copaxone New Drug Application (NDA) and the FDA asked Teva to resubmit the information as a petition. Teva's petition provides new scientific data on gene expression and evidence to support arguments regarding active ingredient sameness, immunogenicity and bioequivalence testing with regard to its relapsing-remitting multiple sclerosis medicine Copaxone. As Teva's data show, it would be contrary to the public's health and welfare to approve a purported generic glatiramer acetate product that, based on current analytical technologies and confirmed by techniques such as gene expression evaluation, at best can be shown to be similar, but clearly not the same as Copaxone. Teva's position is that any potential generic version of Copaxone should use the same gene expression markers and biological pathways to demonstrate sameness, as well as be evaluated via pre-clinical testing and full-scale, placebo-controlled clinical trials with measured clinical endpoints (such as relapse rate) in patients with relapsing forms of multiple sclerosis to establish safety, efficacy and immunogenicity.

Teva Pharmaceutical Updates on U.S. Court of Appeals Uphold Ruling Confirming Invalidity of Baraclude Patent

Teva Pharmaceutical Industries has reported that the U.S. Court of Appeals for the Federal Circuit upheld a ruling by the U.S. District Court for the District of Delaware finding Bristol-Myers Squibb's entecavir compound claim of U.S. Patent No. 5,206,244 invalid. Teva's ANDA for entecavir has received tentative approval from the U.S. Food and Drug Administration (FDA). Teva will finalize the launch plans for this product once it receives final approval from the FDA.

Teva Pharmaceutical Industries Ltd. to Provide Licenses to Perrigo Pharmaceutical Co. and Catalent Pharma Solutions LLC

Teva Pharmaceutical Industries Ltd. has reached a settlement with Perrigo Pharmaceutical Co. and Catalent Pharma Solutions LLC in the ProAir HFA Patent Case. The company will provide licenses to Perrigo and Catalent to sell limited units of Perrigo's generic version of the product for an initial period from December 19, 2016, until June 2018, when the limits will no longer apply. ProAir HFA is indicated in patients 4 years of age and older for the treatment or prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm. This settlement dismisses pending litigation in the U.S. District Court for the District of Delaware in which Teva filed suit against Perrigo and Catalent in response to a notice of the filing of an ANDA containing a paragraph (IV) certification directed against four (4) of the five (5) patents listed in the Orange Book for ProAir HFA.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TEVJF:US $51.85 USD 0.00

TEVJF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TEVJF.
View Industry Companies
 

Industry Analysis

TEVJF

Industry Average

Valuation TEVJF Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TEVA PHARMACEUTICAL IND LTD, please visit www.tevapharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.